Naz Rahman
Stock Analyst at Maxim Group
(0.15)
# 4,102
Out of 4,829 analysts
38
Total ratings
12.5%
Success rate
-44.01%
Average return
Main Sectors:
Stocks Rated by Naz Rahman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLMD Galmed Pharmaceuticals | Downgrades: Hold | n/a | $1.26 | - | 1 | Apr 4, 2025 | |
| NVCT Nuvectis Pharma | Initiates: Buy | $17 | $8.27 | +105.56% | 1 | Apr 2, 2025 | |
| SLXN Silexion Therapeutics | Maintains: Buy | $9 → $5 | $1.00 | +400.55% | 2 | Mar 20, 2025 | |
| SCPH scPharmaceuticals | Maintains: Buy | $20 → $12 | $2.47 | +385.83% | 3 | Mar 20, 2025 | |
| VKTX Viking Therapeutics | Maintains: Buy | $120 → $70 | $28.30 | +147.35% | 5 | Feb 7, 2025 | |
| NRSN NeuroSense Therapeutics | Downgrades: Hold | n/a | $1.10 | - | 2 | Dec 16, 2024 | |
| CING Cingulate | Upgrades: Buy | n/a | $4.03 | - | 4 | Nov 20, 2024 | |
| PALI Palisade Bio | Maintains: Buy | $23 → $8 | $0.77 | +940.31% | 7 | Nov 13, 2024 | |
| PRFX PainReform | Downgrades: Hold | n/a | $1.92 | - | 2 | Oct 24, 2024 | |
| ASRT Assertio Holdings | Initiates: Buy | $3 | $0.62 | +380.85% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $525 → $140 | $6.25 | +2,140.00% | 2 | Mar 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $439.37 | - | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.12 | +83,582.01% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $0.24 | - | 3 | Nov 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5 | $1.24 | +303.23% | 1 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $1.10 | - | 1 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.71 | +121.40% | 1 | Feb 25, 2022 |
Galmed Pharmaceuticals
Apr 4, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.26
Upside: -
Nuvectis Pharma
Apr 2, 2025
Initiates: Buy
Price Target: $17
Current: $8.27
Upside: +105.56%
Silexion Therapeutics
Mar 20, 2025
Maintains: Buy
Price Target: $9 → $5
Current: $1.00
Upside: +400.55%
scPharmaceuticals
Mar 20, 2025
Maintains: Buy
Price Target: $20 → $12
Current: $2.47
Upside: +385.83%
Viking Therapeutics
Feb 7, 2025
Maintains: Buy
Price Target: $120 → $70
Current: $28.30
Upside: +147.35%
NeuroSense Therapeutics
Dec 16, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Cingulate
Nov 20, 2024
Upgrades: Buy
Price Target: n/a
Current: $4.03
Upside: -
Palisade Bio
Nov 13, 2024
Maintains: Buy
Price Target: $23 → $8
Current: $0.77
Upside: +940.31%
PainReform
Oct 24, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.92
Upside: -
Assertio Holdings
Jul 26, 2024
Initiates: Buy
Price Target: $3
Current: $0.62
Upside: +380.85%
Mar 15, 2024
Maintains: Buy
Price Target: $525 → $140
Current: $6.25
Upside: +2,140.00%
Jan 31, 2024
Downgrades: Hold
Price Target: n/a
Current: $439.37
Upside: -
Dec 8, 2023
Initiates: Buy
Price Target: $100
Current: $0.12
Upside: +83,582.01%
Nov 17, 2023
Downgrades: Hold
Price Target: n/a
Current: $0.24
Upside: -
Aug 9, 2023
Initiates: Buy
Price Target: $5
Current: $1.24
Upside: +303.23%
May 9, 2022
Downgrades: Hold
Price Target: n/a
Current: $1.10
Upside: -
Feb 25, 2022
Initiates: Buy
Price Target: $6
Current: $2.71
Upside: +121.40%